Full Business Value: Kairos Pharma Ltd (KAPA)

This price chart illustrates the valuation dynamics of Kairos Pharma Ltd (KAPA), which is currently valued at -0.80. The business relies on strict adherence to temperature controls during drug transport to ensure product integrity. Kairos Pharma Ltd (KAPA) possesses significant market influence through the development of agents that deactivate tumor defenses. However, the strategy is based on a narrow pipeline of developments, leaving the company dependent on clinical trial results.

Kairos Pharma Ltd (KAPA) minimizes operational risks by outsourcing clinical trials for oncology drugs to third-party contractors. This model impacts the structure of liabilities and liquidity, which are aggregated with market capitalization to calculate the enterprise value. This metric reflects the actual acquisition price of the asset by subtracting cash from the total sum of debt and equity. The metric determines the company's resilience to crises and the potential for share price growth. The trend in the company's total valuation allows for an objective assessment of the asset's degree of overheating.